touchHAEMATOLOGY touchHAEMATOLOGY
Leukaemia
Watch Time: 7 mins

Revumenib in relapsed/refractory KMT2Ar acute leukaemia – AUGMENT-101 phase 2 study: Ibrahim Aldoss, ASH 2023

Copy Link
Published Online: Jan 3rd 2024

In KMT2Ar leukaemia, the interaction between menin and KMT2A fusion proteins plays a crucial role in the development of the disease. Despite this, there are currently no approved therapies targeting the menin-KMT2A interaction. Dr Ibrahim Aldoss (City of Hope National Medical Center, Duarte, CA, USA) joins us to discuss revumenib, a novel small-molecule inhibitor targeting this interaction for relapsed/refractory (R/R) KMT2Ar and NPM1-mutated (NPM1m) acute leukaemia, presenting the primary efficacy and safety results in the key phase 2 study, AUGMENT-101 (NCT04065399), and the future directions of revumenib and similar therapies in acute leukaemia treatment.

The abstract entitled ‘Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study‘ was presented at the 65th ASH Annual Meeting and Exposition December 9-12, 2023, in San Diego, CA, USA.

Questions

  1. Could you explain the challenges in treating relapsed/refractory KMT2Ar acute leukaemia and why targeting the menin-KMT2A interaction is crucial? (0:22)
  2. What was the rationale for using revumenib as a potential therapy for KMT2Ar acute leukaemia in the AUGMENT-101 study, and what is its mechanism of action? (1:43)
  3. What were the aims, design, and eligibility criteria of the Phase 2 AUGMENT-101 study? (2:33)
  4. What were the key findings of the study, and how do these compare to existing treatment options? (4:02)
  5. What future research directions do you foresee for revumenib and similar therapies in acute leukaemia treatment? (6:12)

Disclosures: Ibrahim Aldoss is on the advisory board for Syndax.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.

Filmed in coverage of the ASH 2023

Click here for more content on leukaemia

Share this Video
Related Videos In Leukaemia
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72